GlassScriptPhysician profile
Yazan Alkehef
NPI 1487274536
$2,375.15
in general payments reported to CMS, 2019-2025
19 companies · $914 in 2025
The $914 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $384 · 2024: $1,077 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,079 · Education: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,078.66 |
| Education | $296.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $548.03 | 2024-2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $423.46 | 2023-2025 | Lifevest |
| Abbott Laboratories | $222.21 | 2023-2025 | Ensite, Optis, Coroflow |
| Teleflex LLC | $198.86 | 2024-2025 | Turnpike, Guideliner |
| Shockwave Medical, INC | $182.01 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $121.35 | 2024 | Camzyos |
| Penumbra, INC. | $103.08 | 2025 | Indigo System |
| Chiesi USA, INC. | $98.80 | 2023-2025 | Kengreal, Cleviprex |
| Amgen INC. | $97.34 | 2023 | Repatha |
| Merck Sharp & Dohme LLC | $84.27 | 2024 | Verquvo |
| Cardiva Medical, INC. | $76.58 | 2024-2025 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Cordis US Corp. | $48.69 | 2023-2024 | Mynxgrip, Precise Pro Rx |
| Janssen Pharmaceuticals, INC | $48.13 | 2024 | Xarelto |
| Biosense Webster, INC. | $33.46 | 2024 | Carto 3 |
| Pfizer INC. | $21.56 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $19.19 | 2023 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.59 | 2024 | Jardiance |
| Terumo Medical Corporation | $15.82 | 2024 | Azur Cx Detachable |
| Edwards Lifesciences Corporation | $13.72 | 2023 | Sapien 3 Ultra Resilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yazan Alkehef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.